Hormonal
Modest weight loss (5-10%) prevents type 2 diabetes in high-risk individuals, while greater weight loss (>10-15%) can induce remission of established type 2 diabetes, particularly when intervention occurs early in the disease course.
If you have prediabetes or early type 2 diabetes, losing just 5-10% of your body weight can significantly lower your risk of developing full-blown diabetes. If you already have diabetes, losing more weight (10-15%) can potentially put the disease into remission, especially if you act early. Focus on sustainable weight loss through diet, medication, or surgery as advised by your doctor, rather than just managing blood sugar with pills alone.
In clinical trials, modest weight loss (5%–10%) can prevent T2D in high-risk individuals with subclinical disease... In those with established T2D, early weight loss intervention can remit the condition... >10% weight loss may remit T2D
Why this rating
Supported by multiple randomized controlled trials (Diabetes Prevention Study, DiRECT) and meta-analyses.
Source
Obesity as a <scp>multisystem</scp> disease: Trends in obesity rates and <scp>obesity‐related</scp> complications
Shohinee Sarma et al. · Diabetes Obesity and Metabolism · 2021
DOI 10.1111/dom.14290
More from this paper
- Obesity is a multisystem disease where excess adiposity causes comorbidities across multiple organ systems (cardiovascular, metabolic, malignancy, mental health), and weight loss can prevent or reverse many of these conditions.Strong
- Bariatric surgery is the most efficacious treatment for sustained weight loss and can induce long-term remission of type 2 diabetes in approximately 30% of patients, with Roux-en-Y gastric bypass being potentially more effective than sleeve gastrectomy for T2D remission.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →